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Abstract: Developing a vaccine against the global pandemic SARS-CoV-2 is a critical area of active
research. Modelling can be used to identify optimal vaccine dosing; maximising vaccine efficacy
and safety and minimising cost. We calibrated statistical models to published dose-dependent
seroconversion and adverse event data of a recombinant adenovirus type-5 (Ad5) SARS-CoV-2
vaccine given at doses 5.0 × 1010, 1.0 × 1011 and 1.5 × 1011 viral particles. We estimated the optimal
dose for three objectives, finding: (A) the minimum dose that may induce herd immunity, (B) the
dose that maximises immunogenicity and safety and (C) the dose that maximises immunogenicity
and safety whilst minimising cost. Results suggest optimal dose [95% confidence interval] in viral
particles per person was (A) 1.3 × 1011 [0.8–7.9 × 1011], (B) 1.5 × 1011 [0.3–5.0 × 1011] and (C) 1.1
× 1011 [0.2–1.5 × 1011]. Optimal dose exceeded 5.0 × 1010 viral particles only if the cost of delivery
exceeded £0.65 or cost per 1011 viral particles was less than £6.23. Optimal dose may differ depending
on the objectives of developers and policy-makers, but further research is required to improve the
accuracy of optimal-dose estimates.
Keywords: dosing; dose-response; adenovirus-vectored vaccines; dose dynamics; COVID-19
1. Introduction
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has been an un-
precedented burden on global health throughout 2020 [1]. Due to the health risks associated
with infection, countries have had to implement policies of isolation and quarantine, caus-
ing global disruption to economic and health systems [2]. Vaccination is a vital tool in
improving global health [3] and an effective vaccine against SARS-Cov-2 could drastically
reduce the spread of this highly infectious pathogen. There is an urgent need to accelerate
the development of a SARS-CoV-2 vaccine to protect the population [4]. However, main-
taining safety and immunogenicity standards within vaccine development is paramount.
Decisions relating to vaccine development need to be made quickly and accurately. One
important decision is determining vaccine dose, defined as the quantity or magnitude of
vaccine given.
Model-based drug development is commonly used to accelerate drug decision mak-
ing, and the field of Immunostimulation/Immunodynamic (IS/ID) modelling has been
developed to adapt these methods for vaccine development [5]. IS/ID modelling has
shown promise in discovering optimal dose for TB and influenza inoculations [6,7] and for
exploring dose-response trends for adenoviral-vectored vaccines [8], however, the previous
works have focused entirely on optimising dose with respect to immunological response.
In these studies, the modelling of dose-response and hence finding the dose that maximises
response can be considered single-objective optimisation problems.
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Whilst optimising response with respect to vaccine dose is essential to ensuring ef-
fective vaccination, the change in financial cost and safety of vaccination with respect to
vaccine dose are also important. A vaccine should ideally maximise protective immuno-
genicity, minimise the risk of vaccine-related toxicity and minimise the cost of using that
vaccine. Optimising dose in relation to immunogenicity, safety and cost is a multi-objective
or multi-criteria-decision-analysis problem [9]. Using models to analyse the dose-response,
dose-safety and dose-cost relationships can provide insight into the multi-dimensional
dose-utility curve and hence optimal dose. There may also exist cases where the cost of
vaccination can be ignored, for example, if the vaccine is not limited in supply. This could
also be true for cases where there is a very high willingness to pay for vaccination by
policymakers, which permits costs to be nearly ignored to ensure a maximum reduction in
disease burden.
Approximately 180 SARS-CoV-2 vaccines are in development [10], and there is much
interest in which vaccines may offer the greatest efficacy in reducing the burden of SARS-
CoV-2 on global health [11–13]. Not only should the dose of any vaccine implemented
be optimised with regards to safety, immunogenicity and cost, but appropriate dosing is
equally important to ensure that unbiased estimate of vaccine immunogenicity and safety
is used. In addition to establishing optimal dose at an individual level, the potential of a
candidate vaccine to induce herd immunity in an entirely vaccinated population can also
be considered.
Whilst accelerating these decisions and improving dosing is important now [14], it
is also hoped that modelling and multi-objective optimisation can aid in rapid vaccine
response to future epidemics.
In this work, we aimed to optimise the dose of a recombinant adenovirus type-5 (Ad5)
vectored SARS-CoV-2 vaccine using IS/ID modelling and multifactorial optimisation. Our
objectives were:
(1) Using published data, calibrate mathematical models to the relationship between
dose and seroconversion, safety and cost of a single inoculation.
(2) Identify the minimum dose that is predicted to theoretically induce herd immunity.
(3) Identify the dose that maximises immunogenicity and safety.
(4) Identify the dose that maximises immunogenicity and safety whilst minimising cost.
2. Materials and Methods
2.1. Data
Data were extracted from a published phase 1 study of a SARS-Cov-2 adenoviral-based
vaccine [15]. Data on neutralising antibody-based seroconversion and adverse events were
extracted for 108 healthy human participants inoculated with the candidate vaccine on day
0. Individuals were divided into three dose groups (5 × 1010, 1 × 1011 and 1.5 × 1011 Viral
Particles (VP)) and their responses were measured at day 28.
Seroconversion was chosen as a surrogate of protective immunity and was defined as
a neutralising antibody response post-vaccination of at least a four-fold increase relative to
baseline, above which an individual was protected [16].
Safety was defined by the proportion of individuals that experienced adverse events
within 0–28 days post-vaccination. Vaccine adverse events can be graded depending on
severity (Table 1), with grade 3 or above considered severe [17,18]. As a measure of safety,
we considered both the proportion that experienced “any grade” adverse events and the
proportion that experienced grade 3 or above adverse events. Whilst the designation
“Grade 3+” is used to be consistent with the terms used by the original authors, no adverse
events above grade 3 were reported.
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Table 1. Description of adverse event grading in vaccine clinical trials.
Adverse Reaction Grade General Descriptions
1 Mild. Does not interfere with normal activity
2 Moderate. Interference with normal activity. Little or no treatment required.
3 Severe. Prevents normal activity. Requires treatment.
4 Serious or Potentially Life-Threatening. Generally requires hospitalisation and stopping of anyclinical trial where this grade is observed.
2.2. Objective 1. Using Published Data, Calibrate Mathematical Models to the Relationship
between Dose and Seroconversion, Safety and Cost of a Single Inoculation
2.2.1. Dose-Seroconversion Relationship
We calibrated a sigmoid function to the dose-seroconversion data using the nls func-
tion in R [19,20]. Sigmoid functions are commonly used to describe biological processes,
including in both drug and vaccine response modelling. The formula is




where Dose was log10 (Viral Particles), and BaseResponse (the minimum output of the
function), MaxResponse (the maximum output of the function), Dose50 (the dose which
defines the functions midpoint) and Scale (which determines the steepness of the curve)
were the model parameters.
We also calibrated a representative non-saturating (“peaking”) curve, using the meth-
ods discussed in [8]. However, as these methods did not support the non-saturating curve
providing a better description of the data, we assume that the dose-response follows a
sigmoidal function (Supplementary S1).
In the absence of seroconversion data from a placebo group, a base seroconversion
rate of 0% was assumed (BaseResponse = 0). We predicted the dose-seroconversion curve
for doses of up to 1015 VP, to ensure previous adenoviral dosing ranges are explored [21]
and state the dose that would induce 50% and 90% seroconversion.
2.2.2. Dose-Safety Relationship
We calibrated a sigmoid function (Equation (1)) to the dose—”any grade adverse
event” data using the nls function in R, and another to the dose—”grade 3+ adverse event”
data. Again, in the absence of a placebo group, a base adverse event rate of 0% was
assumed for both curves (BaseResponse = 0). Further, we assumed that for sufficiently large
doses, 100% of individuals would experience adverse events. We predict the probability of
an adverse event for doses of up to 1015 VP.
Lastly, we found the doses for which the proportion of individuals that would expe-
rience grade 3+ adverse events above the thresholds of 30% and 17%. 30% of grade 3+
adverse events has been defined as a threshold for unacceptable toxicity in dose-escalation
studies [22–24]. However, of the commonly CDC recommended vaccines, the largest grade
3+ adverse reaction rate is 17% for the Shingrix herpes zoster vaccine [25].
2.2.3. Dose-Cost Relationship
We assumed that the cost of a single individual receiving a vaccination can be de-
scribed by
CostTotal(Dose) = CostDelivery + CostDose−dependant(Dose) (2)
where CostTotal(Dose) was the total cost in British Pounds Sterling (GBP, £) to vaccinate
one person with a given dose. We assumed that this was the sum of “Delivery” costs, which
are independent of dose, and the dose-dependent cost. Expected costs for doses of up to
1015 VP were calculated using this formula and parameters in Table 2.
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Table 2. Parameter values for the cost function. Where needed, a conversion rate of 0.78 U.S. Dollars per GBP was used [26], and a 10-year inflation rate was estimated as 1.35 2020 GBP per 2010
GBP Pound [27].
Name of Parameter Value Unit Description References
CostPersonnel(£ per vaccination) = 4.398707
AnnualWage 30,615 £ per years GBP per NHS Band 5 Income per annum (2020/21) [28]




vaccination Recommended hours per vaccination appointment [30]
CostStorage(£ per vaccination) = 0.014
CostStoragepermonth 0.014 £ per month
GBP per vaccination per month’s storage. Converted and adjusted for
inflation from $0.014 2010 USD. [31]
Costmaterials(£ per vaccination) = 0.83
CostGloves 0.08 £ per vaccination
GBP of gloves for one vaccination. Converted and adjusted for
inflation from $0.08 USD. [31]
CostAlcohol 0.03 £ per vaccination
GBP of sterilising alcohol for one vaccination. Converted and
adjusted for inflation from $0.03 2010 USD. [31]
CostPFS 0.40 £ per vaccination
GBP of the pre-filled syringe for one vaccination. Converted and
adjusted for inflation from $0.39 2010 USD. [31]
CostNeedles 0.32 £ per vaccination
GBP of needle for one vaccination. Converted and adjusted for
inflation from $0.31 2010 USD. [31]
Costperviralparticle(£ perVP) = 7.6 × 10−12
CostAdenoviralBatch 342,000 £ per Batch
GBP per single-use reference process batch (converted from
450,000 US Dollars) [32]
Adenoviral
Concentration 9 × 10
13 VPper L Viral Particles per litre in single-use reference process batch [32]
Batchvolume 500 L per Batch Volume of Adenovirus produced in single-use reference process batch [32]
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Specifically, the delivery costs included the cost of disposable materials used in vacci-
nation (gloves, sterilizing alcohol, prefilled syringes, needles), storage (assumed to be 1
month of storage costs), and personnel costs (15 min of nursing time). The delivery cost
formula was therefore calculated as
CostDelivery(Dose) = CostMaterials + CostStorage + CostPersonnel (3)
where
CostMaterials(Dose) = CostGloves + CostAlcohol + CostPFS + CostNeedles (4)
CostStorage(Dose) = CostStoragepermonth × 1(months) (5)
CostPersonnel(Dose) = (AnnualWage ÷ AnnualHours)× Timepervaccination (6)
The dose-dependent cost was the cost of the manufactured adenoviral vaccine mea-
sured in viral particles, assuming bulk production, which increased linearly with the
vaccine dose. The dose-dependent cost formula was therefore calculated as
CostDose−dependent = Viralparticlespervaccination(Dose)× Costperviralparticle (7)
With
Costperviralparticle = CostAdenoviralBatch ÷ (AdenoviralConcentration × BatchVolume) (8)
These costs were a simplification of real-world costs but represent an approximate
cost of vaccination. The delivery cost of vaccination (CostDelivery) was calculated as £5.24,
and the cost per 1011 VP (CostDose-dependent) of adenovirus was £0.76 ( Table 2).
2.3. Objective 2. Identify the Minimum Dose that Is Predicted to Theoretically Induce
Herd Immunity
An optimal vaccine dose should maximise response (maximise the proportion that
will seroconvert), safety (minimise the proportion that experience adverse events), and
affordability (minimise cost per vaccination). Increasing dose may increase seroconversion,
but would also increase cost and adverse event prevalence. Vaccinating a population is
often done to induce herd immunity, and so a factor in selecting the optimal dose is whether
that dose could induce herd immunity in an entirely vaccinated population. Therefore, one
approach to dose-optimisation is to choose a dose that can induce herd immunity within
the population, and specifically to choose the minimum such dose to minimise cost and
adverse event prevalence.
We used the suggested 65.5% of the population required to be protected to cause herd
immunity in the United Kingdom (UK) [33] to establish whether there exist doses for this
vaccine that could induce this 65.5% seroconversion and hence induce herd immunity in
an entirely vaccinated population. We then identified the minimum such dose that could
do so. A 95% confidence interval for optimal dose was determined using a parametric
bootstrapping approach (Supplementary S2.3.1).
2.4. Objective 3. Identify the Dose that Maximises Immunogenicity and Safety
Another approach to dose optimisation is to choose the dose which maximises the
proportion of individuals that “safely” seroconvert. To do this, a multifactorial utility
function was derived, defined here as a mathematical formula that estimates the “worth”
or utility of doses relative to each other.
Using the assumption that the probability of seroconversion, Ps, and the probability
of grade 3+ adverse events, Pt, were mutually independent, the probability of a safe
seroconversion was equal to
PS × (1 − Pt) (9)
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(Figure 1). Therefore, the utility function, UCostless, to be maximised was
UCostless(Dose) = Ps(Dose)× (1 − Pt(Dose)) (10)




Figure 1. Venn diagram representation of possible outcomes of inoculation, where 
the left set includes individuals that experience grade 3+ adverse events and the right set 
includes individuals that experience seroconversion. We aimed to maximise the number 
of individuals that experience seroconversion and do not experience grade 3+ adverse 
events, represented in the green segment of the diagram. Black diamonds represent indi-
viduals that experience both outcomes, black pentagons represent individuals that expe-
rience grade 3+ adverse events with no seroconversion, and black triangles represent in-
dividuals that experience neither outcome. 
2.5. Objective 4. Identify the Dose that Maximises Immunogenicity and Safety Whilst 
Minimising Cost 
We can also include the increased cost associated with an increased dose into the 
previous utility function (Equation (10)). In the case where cost is included as a potential 
limiting factor, a potential costed utility function was  𝑈 (𝐷𝑜𝑠𝑒) = 𝑃 (𝐷𝑜𝑠𝑒) × (1 − 𝑃𝑡(𝐷𝑜𝑠𝑒))𝐶𝑜𝑠𝑡 (𝐷𝑜𝑠𝑒)  (11) 
Using this utility function, we predicted the optimised dose for maximising serocon-
version and minimising adverse events and cost. Note that UCostless(Dose) (Equation (10)) is 
precisely the numerator of the UCosted(Dose) (Equation (11)). A 95% confidence interval for 
optimal dose was again determined using a parametric bootstrapping approach (Supple-
mentary S2.3.2). 
Threshold Analysis  
Due to the difficulty in accurately estimating cost parameters, we conducted a thresh-
old analysis on the parameter values of the cost model (Equations (3)–(8)). This was con-
ducted to determine how much error would be needed in our costing model parameters 
to qualitatively alter the optimal predicted dose. We chose 5 × 1011, 1 × 1011 and 5 × 1010 VP 
as the thresholds of interest.  
Figure 1. Venn diagram representation of possible outco es of inoculation, where the left set includes individuals that
experience grade 3+ adverse events and the right set includes individuals that experience seroconversion. We aimed
to maximise the number of individuals that experience seroconversion and do not experience grade 3+ adverse events,
represented in the green segment of the diagram. Black diamonds represent individuals that experience both outcomes,
black pentagons represent individuals that experience grade 3+ adverse events with no seroconversion, and black triangles
represent individuals that experience neither outcome.
Optimal dose was defined as the dose that maximised this function. A 95% confidence
interval for optimal dose was determined using a parametric bootstrapping approach
(Supplementary S2.3.2).
2.5. Objective 4. Identify the Dose that Maximises Immunogenicity and Safety Whilst
Minimising Cost
We can also i clude the increased cost associated with an increase dose into the
previous utility function (Equation (10)). I the case where cost is included as a potential
limiting factor, a potential costed utility function was
UCosted(Dose) =
Ps(Dose)× (1 − Pt(Dose))
CostTotal(Dose)
(11)
Using this utility function, we predicted the optimised dose for maximising serocon-
version and minimising adverse vents and cost. Note that UCostless(Dose) (Equation (10))
is precisely the numerator of the UCosted(Dose) (Equation (11)). A 95% confidence inter-
val for optimal dose was again determined using a parametric bootstrapping approach
(Supplementary S2.3.2).
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Threshold Analysis
Due to the difficulty in accurately estimating cost parameters, we conducted a thresh-
old analysis on the parameter values of the cost model (Equations (3)–(8)). This was
conducted to determine how much error would be needed in our costing model param-
eters to qualitatively alter the optimal predicted dose. We chose 5 × 1011, 1 × 1011 and
5 × 1010 VP as the thresholds of interest.
To conduct a threshold analysis of parameters CostDelivery, we fixed all other parameters
at the calibrated/literature derived value and allowed CostDelivery to vary. The region over
which we varied CostDelivery was +/− 3 orders of magnitudes of the value (£5.24) we used
in the main model. In other words, we considered the effect of CostDelivery being 1000 times
larger or smaller (from £0.0052 per vaccination to £5240 per vaccination) on the prediction of
optimal dose. This range was considered certainly to almost contain a reasonable estimate
of the dose-independent costs of a single vaccination. This procedure was then repeated
for Cost per 1011 viral particles, ranging from £0.00076 to £760 per 1011 VP.
We found the parameter ranges for which the dose that optimised UCosted(Dose) were
above and below the stated thresholds (5 × 1011, 1 × 1011, 5 × 1010 VP).
3. Results
3.1. Objective 1. Using Published Data, Calibrate Mathematical Models to the Relationship
between Dose and Seroconversion, Safety, and Cost of a Single Inoculation
3.1.1. Does-Seroconversion Relationship
The empirical data showed that doses of 5.0 × 1010, 1.0 × 1011 and 1.5 × 1011 in-
duced 50%, 50%, 75% seroconversion on day 28, respectively. The calibrated saturating
dose-seroconversion curve is displayed in Figure 3.3a. 50% and 95% seroconversion were
predicted at a dose of 5.9 × 1010 and 2.4 × 1012 VP, respectively. Population demograph-
ics including age, gender and pre-existing adenovirus neutralising antibody titre were
described [15] (Supplementary S3).
3.1.2. Dose-Safety Relationship
The study showed that doses of 5 × 1010, 1 × 1011 and 1.5 × 1011 VP induced 86%,
83% and 75% any grade adverse events and 6%, 6% and 17% grade 3+ adverse events,
respectively. The calibrated saturating dose-adverse event curves are displayed in Figure
3.3b,c. The two thresholds of safety we previously chose were 17% and 30% grade 3+
adverse reaction proportion. The calibrated dose-adverse curve predicted that a rate of
adverse events greater than 17% occurs for doses in excess of 1.58 × 1011 VP and exceeds
30% at 2.45 × 1011 VP.
3.2. Objective 2. Identify the Minimum Dose that Is Predicted to Theoretically Induce
Herd Immunity
The dose-seroconversion prediction for the minimum dose that could induce the-
oretical herd immunity is shown in Figure 3a. Given that an estimate for the critical
herd immunity threshold in the UK has been estimated as 65.5%, a dose of 1.3 × 1011
VP would be required to reach this threshold, assuming the entire UK population was
vaccinated. The 95% confidence interval for optimal dose was (8.0 × 1010, 7.9 × 1011)
(Supplementary S2.3.1). Using the dose-safety model, this dose was predicted to cause
13.5% of vaccinated individuals to have a grade 3+ adverse event.
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Figure 2. The three curves displaying the relationship between dose and (a) percen ag of vaccinated
individuals predicted to seroconvert, (b) percentage of vaccinated individuals predicted to experience
any grade adverse events and (c) percentage of vaccinated individuals predicted to experience grade
3+ adverse events. The curves are sigmoid curves calibrated to data. Black dots r prese t the data
the curves were calibrated to. In (a) the solid and dashed red lines show respectively the doses for
which 50% and 90% of individuals are predicted to seroconvert. In (c) the solid and dashed red lines
show respectively the doses for whi h 17% and 30% of individuals are predicte to experience gr de
3+ adverse events. We note that the percentage of individuals experiencing any grade adverse events
in (b) qualitatively decreased with increasing dose, whereas the model curve was increasing. This
decreasing trend could be explained by the expected stochasticity in the data, hence the sigmoid
model did not seem unreasonable (Supplementary S4).
3.3. Objective 3. Identify the Dose that Maximises Immunogenicity and Safety
The dose-utility prediction is shown in Figure 3b. The dose that optimised this function
was 1.5 × 1011 VP (Figure 3b, red diamond). It was predicted that dosing at this magnitude
would lead to a seroconversion rate of 67.6%, and cause 15.8% f vaccinated individuals to
have a grade 3+ adverse event (83.0% any grade adverse events).
Sensitivity analysis (Supplementary S2) showed that the prediction of the optimal dose
was most sensitive to variance in the Dose50 parameter of the dose-seroconversion sigmoid
function and the Dose50 parameter of the dose-safety sigmoid function (Supplementary
S2.2.1). These were respectively equal to the doses that were predicted to induce 50%
of vaccinated individuals to seroconvert and 50% to experience grade 3+ adverse events
(with an increase in these parameters qualitatively shifting the curves in Figure 3.3a,c
to the right). The 95% confidence interval for optimal dose was (2.9 × 1010, 5.0 × 1011)
(Supplementary S2.3.2).
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Figure 3. Displays of the predicted utility of doses between 100 and 1015 VP. (a) shows dose-
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(c) shows the relationship between dose and the costed utility function. The black dots represent
Table 1. 3 × 1011, (b) 1.5 × 1011 VP and (c) 1.1 × 1011 VP.
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3.4. Objective 4. Identify the Dose that Maximises Immunogenicity and Safety Whilst
Minimising Cost
The dose-utility relation including cost is shown in Figure 3c. The dose that optimised
this function was 1.1 × 1011 VP. It was predicted that dosing at this magnitude would
lead to a seroconversion rate of 62.20%, cost £6.07 per dose, and cause 10.32% of vacci-
nated individuals to have a grade 3+ adverse event (82.2% any grade adverse events).
The 1 × 1011 VP dose had the highest utility of the doses tested in the study, and both of
the 5 × 1010 and 1.5 × 1011 VP doses appeared to be near-optimal. This analysis, therefore,
suggested that if the cost was included in the utility function then a marginally reduced
dose was found optimal relative to the costless utility function. The predicted cost is within
the expected range [$5–$37] for a single SARS-CoV-2 vaccine dose [34].
Again, we found that the prediction of the optimal dose was most sensitive to variance
in the Dose50 parameter of the dose-seroconversion sigmoid function. This parameter is
equal to the dose that we predict would induce 50% of vaccinated individuals to seroconvert
(with an increase in these parameters qualitatively shifting the curve in Figure 3.3a to the
right). Optimal dose was not sensitive to <10% error in the estimation of CostDelivery or
Costperviralparticle (Supplementary S2.2.2). The 95% confidence interval for optimal dose
was (2.1 × 1010, 1.5 × 1011) (Supplementary S2.3.3).
Threshold Analysis
For CostDelivery, we found that the predicted optimal dose was independent of the
parameter value for large values (Figure 4). We found that the optimal dose was in excess
of 1 × 1011 and 5 × 1010 VP for CostDelivery values in excess of £3.79 and £0.65, respectively
(hence optimal dose was only less than 5 × 1010 VP for CostDelivery less than £0.65). These
values were respectively 0.7 and 0.1 times the value that was used in the main analysis. We
find that the optimal dose was not in excess of 5 × 1011 VP for any CostDelivery values.
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For Cost per 1011 viral particles, we found that the optimal dose was independent of
the parameter value for large values (Figure 5). We found that the optimal dose was in
excess of 1 × 1011 and 5 × 1010 VP for Cost per 1011 viral particles values in less than £1.06
and £6.23, respectively (hence optimal dose was only less than 5 × 1010 VP for Cost per
1011 viral particles greater than £6.24). These values were respectively 1.3 and 8.2 times the
value that was used in the main analysis. We find that the optimal dose was not in excess
of 5 × 1011 VP for any Cost per 1011 viral particles values.
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If Cost per 1011 viral particles was less than 0.2 times CostDelivery, then the predicted optimal
dose was between 1.0 × 1011 and 1.5 × 1011 VP.
4. Discussion
Vaccination is an important part of global healthcare and disease prevention. Vac-
cination must be protective, safe, and affordable at a population level, and all of these
factors may be impacted by dose. We used modelling and multifactorial optimisation
approaches to predict the optimal dose of an adenoviral vectored vaccine against SARS-
CoV-2 based on protection, safety and cost. A dose of 1.1 × 1011 VP of this vaccine was
found to be optimal with respect to seroconversion, safety and cost. However, an increased
dose of 1.3 × 1011 VP or 1.5 × 1011 VP could be justified depending on the objectives of
developers and policymakers. These methods highlight how quantitative analysis can be
used to ensure that vaccines are dosed optimally, and could aid in accelerating vaccine
development.
The IS/ID methods used in this work have previously been used to analyse and
optimise vaccine dose-response [7,34]. Compared to those studies, this work is novel in its
inclusion of dose-safety and dose-cost models and multi-objective optimisation methods.
This work used data published as part of a vaccine development protocol, which highlights
how these methods do not require additional complexity in trial design. Using only the
published data, we were able to hypothesize the best dosing for a candidate SARS-CoV-2
vaccine. Such methods could routinely be used to evaluate dose for other clinical and
preclinical vaccine trials. Given the pandemic setting in which the SARS-CoV-2 candidates
are being developed where trials are being accelerated and progressing faster than would
normally be expected, modelling may be even more of an important adjunct in ensuring
optimal vaccine dosing.
We had to make some assumptions in this work. Firstly, the assumed cost function
was based on a si plification of a vaccine campaign cost estimate suggested by the World
Health Organisation [35,36], discounting costs incurred by vaccine wastage and incre-
mental costs of mai taining hospitals and clinics. Ad itionally, the exact cost per viral
particle of the vacci e was unknow and would vary with production scale, however, the
thres old analyses showed that the optimal-dose prediction may still be robust d spite
this uncertainty. As this was a financial rather than economic analysis, we did not account
for “Disability Adjusted Life Years” [37] (DALYs) gained by reducing SARS-CoV-2 impact
or societal costs incurred by missing work to be vaccinated. Including DALYs or similar
measures into the cost function may give a greater understanding of whether this vaccine
would be a cost-effective approach to controlling SARS-CoV-2. However, the focus of the
work was not in producing a fully functional economic evaluation of implementing this vac-
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cine. Additionally, to analyse potential DALYs averted would have required the inclusion
of economic and epidemiological models that were beyond the scope of this paper.
An additional assumption of the utility model was that avoiding grade 3+ adverse
events was as important to the utility function as inducing seroconversion. To address this,
a weighting function may be applied if the expected discomfort of a SARS-CoV-2 infection
is greatly in excess of a grade 3+ adverse event and a discomfort ratio between these two
outcomes can then be determined (see Supplementary S6). Alternatively, thresholds for
acceptable levels of seroconversion and adverse events could be determined, and any doses
predicted to meet these thresholds considered optimal.
We found that dosing at 2.45 × 1011 VP would likely induce grade 3+ adverse events
in greater than 30% of individuals vaccinated, which is a typical threshold for safety in
clinical trials. Previous work has found that human-hosted adenoviral vector vaccine trials
typically do not dose in excess of 2 × 1011 [21]. This suggests that adenoviral vaccine
trials are being dosed at magnitudes that ensure that grade 3+ adverse reactions remain
below the 30% threshold. However, for this vaccine, the available data was not sufficient to
determine whether the dose-seroconversion curve shape was better described by a peaking
or saturating curve shape. This implies that we cannot be confident that the percentage of
individuals that seroconvert would continue to increase as dose increases beyond those
empirically tested. This is likely the result of using too few doses or not dosing at a
sufficiently large dose to observe peaking or saturating dose-response behaviour. We
have previously shown that curve shape could not be determined for 75% of adenoviral
dose-response data [8]. However, in this case, it is possible that dosing at a large enough
magnitude to determine curve shape could cause an unacceptable number of grade 3+
adverse events.
There were limiting factors to our analyses. We had to assume that seroconversion
implies that an individual was protected against SARS-CoV-2 infection. This seemed
appropriate in the absence of a validated model for predicting SARS-CoV-2 protective
immunity or a challenge study, but could be updated as a greater understanding of SARS-
CoV-2 correlates of protection is developed [38–40]. Additionally, we had to assume that the
base seroconversion and adverse events percentage was 0%. That is to say that individuals
that received no vaccine dose would not seroconvert or experience any adverse events. This
was reasonable given the lack of a placebo group in the data but may limit the predictive
validity of toxicity and seroconversion at lower doses.
Further limitations are due to the non-inclusion of potential population effects and
covariates in the model. The proportion of individuals that the vaccine needs to protect may
change depending on the number of individuals that have been previously infected or on
the extent that a prior infection provides lasting immunity. Additionally, prior adenoviral
exposure or age of vaccinated individuals could impact the probabilities of seroconversion
and adverse events. Individuals younger than 45 were shown to be less likely to experience
fever and more likely to experience seroconversion [15] which, given that there existed
some heterogeneity in age distribution between dosing groups in the data, may impact the
model’s future predictive validity. Finally, given that no grade 4 (serious/life-threatening)
events were observed, no analyses could be done to assess the dose-varying probability of
these events.
This work implies that the doses that have been trialled for this vaccine were near the
theoretical optimal dose. Whilst we predicted 1.1 × 1011 VP of the vaccine would be the
dose that optimises safety, cost, and protective immunity, if vial size restricts precision on
which doses can be administered then, of the previously empirically tested doses, both
the 1.0 × 1011 and 1.5 × 1011 doses could be reasonable. We also predicted that inducing
complete herd immunity in an otherwise entirely susceptible population may be feasible
with this vaccine given 100% uptake, but we predict that approximately 13.5% of vaccinated
individuals would experience grade 3+ adverse events and that this would require a dose
of at least 1.3 × 1011 VP. As the dose optimising the costless utility function was in excess of
this threshold, but not the dose optimising the utility function with cost, this work implies
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that to fully protect the UK population with this vaccine would require accepting some
level of cost inefficiency.
We anticipate the following future work. Firstly, to ensure that the models used to
make these suggestions are accurate and valid, further clinical trials would need to be
conducted, preferably at a wider spread of doses for which empirical data do not yet
exist. In particular, a placebo group could allow for adjustment of the assumption that
individuals that receive no vaccine dose do not seroconvert or experience any adverse
events. This may help to increase accuracy in the prediction of optimal dose. Secondly,
the simple assumptions made in developing the optimisation utility functions mean the
function could be applied broadly but should be adapted to the specific knowledge and
needs of vaccine developers and policymakers. For example, including a specific adverse
reaction threshold that has been defined in the study protocol, or by predicting protective
immunity as highlighted in [41].
Thirdly, these methods applied to other candidate SARS-CoV-2 vaccines may provide
a method to compare the relative utility of these candidates. Fourthly, with respect to the
dose-safety model, including a weighting of the relative risks/discomforts associated with
SARS-CoV-2 infection/adverse events would be informative. Fifthly, the data was gathered
from individuals residing in the Wuhan region only. Similar data should be gathered from
other populations to assess potential differences in response and safety. Given sufficient
data, incorporating the covariates of age and pre-existing rAd5 neutralising antibody titre
into the model could aid in predictive validity across various populations and in assessing
dose effect.
Sixthly, this work only considers a single dose of the vaccine and response at one time-
point. Further modelling could be attempted to address dose-optimisation the different
time points or to consider a prime-boost paradigm. Finally, the dose-seroconversion and
dose-safety models developed in this work could also be incorporated into the epidemi-
ologic transmission and economic models to more accurately determine the health and
economic impact of a given dose.
5. Conclusions
The SARS-CoV-2 pandemic has caused global health and economic issues and has
led to increased pressure to rapidly develop a potentially life-saving vaccine. Dose is a
key attribute in determining vaccine immunogenicity, safety and cost, and therefore dose-
optimisation is an important aspect of vaccine development. Modelling and multifactorial
optimisation methods allow for fast, quantitatively-based dosing decisions. Given the
increased pressures for rapid vaccine development in response to pandemics, these tools
should be considered a useful approach to accelerating vaccine development.
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